Calculating the pharmacokinetic parameters of cefaclor in healthy volunteers using limited sampling model

Abstract

Abstract: AIM: To set a linear regression model in selecting 1-4 point blood concentrations as biomarkers for predicting AUC_0-240min and C_max in individual therapy. METHODS: The blood concentrations of cefaclor were determined by HPLC and the data within 240 min were used for modeling. The reliability and stability of the model was evaluated with the absolute prediction error (APE) by Jackknife method and plotting. RESULTS: A limited sampling model was established with 1-4 point concentrations by the regression model with plotting. One point for prediction of AUC_0-240min showed 15% APE 47.9% in subjects, but two, three or four points could obtain better prediction with less than 15% APE in all subjects. There were the same results in the prediction of C_max in the subjects. CONCLUSION: Using limited sampling model, two to four blood concentration points of cefaclor can used to predict the AUC_0-24h and Cmax for individual therapy.

Key words: Cefaclor, Limited sampling model, Jackknife, Mathematical model

CLC Number:

R969

HUANG Xiao-hui¹, HUANG Ji-han², WANG Qin¹, WANG Kun². Calculating the pharmacokinetic parameters of cefaclor in healthy volunteers using limited sampling model[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2012, 17(4): 421-427.

References

[1] Johnston A, Sketris I, Marsden JT, et al. A limited sampling strategy for the measurement of cyclosporine AUC[J]. Transplant Proc, 1990, 22(3): 1345-1346.
[2] Suarez-Kurtz G, Vicente FL, Ponte CG, et al. Limited-sampling strategy models for estimating the area under the plasma concentration-time curve for amlodipine[J]. Eur J Clin Pharmacol, 1999, 55(9): 651-657
[3] Monchaud C, Rousseau A, Leger F, et al. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC_(0-12) monitoring in cardiac transplant recipients over the first year post-transplantation[J]. Eur J Clin Pharmacol, 2003, 58(12): 813-820.
[4] Zicheng Y, Peijun Z, Da X, et al. Investigation on pharmacokinetics of mycophenolic acid in Chinese adult renal transplant patients[J]. Br J Clin Pharmacol, 2006, 62(4): 446-452.
[5] Bolon-Larger M, Chamouard V, Bressolle F, et al. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A[J]. Ther Drug Monit, 2007, 29(1): 20-26.
[6] Dickinson L, Back D, Pozniak A, et al. Limited-sampling strategy for the prediction of boosted hard-gel saquinavir exposure at a dosage of 1000/100 mg twice daily in human immunodeficiency virus-infected individuals[J]. Ther Drug Monit, 2007, 29: 361-367.
[7] Jiao Z, Zhong JY, Zhang M, et al. Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limited sampling strategies[J]. Eur J Clin Pharmacol, 2007, 63(1): 27-37.
[8] ZeLuff B, Catchpole M, Lowe P, et al. Cefadroxil compared with cefaclor in the treatment of streptococcal pneumonia in adults[J]. Drugs, 1986, Suppl 32:39-42.
[9] Quenouille M. Notes on bias in estimation. Biometrika, 1956, 61:353-360
[10] Efron B. Bootstrap Methods: Another Look at the Jackknife[J]. The Annals of Statistics, 1979, 7(1):1-12.
[11] Dupuis LL, Sibbald C, Schechter T, et al. IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant: limited sampling strategies[J]. Biol Blood Marrow Transplant, 2008, 14(5): 576-582.

[1]	LIU Yan, LIU Jiali, JIA Yuanwei, ZHOU Fang, WANG Guangji, ZHANG Jingwei. Advances in the evaluation of intra-tumoral delivery of antitumor drugs [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(10): 1151-1159.
[2]	HUANG Ji-han, WANG Kun, XU Ling, HE Ying-chun, LI Lu-jin, YANG Juan, SHENG Yu-cheng, ZHENG Qing-shan. Biomarker finding of individual salviol B exposures in healthy subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(5): 510-516.
[3]	ZHANG Xiu-hong, MA Zhang-qing, GUI Chang-qing, SONG Jian-guo. Effects of probenecid on intestinal absorption of cefaclor in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2008, 13(12): 1344-1349.
[4]	XU Ling, LV Ying-hua, YANG Juan, HE Ying-chun, LIU Hong-xia, SUN Rui-yuan, ZHENG Qing-shan. Prediction of the AUC and the comparison of approaches for validation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(9): 1062-1067.
[5]	LV Ying-hua, XU Ling, YANG Juan, HE Ying-chun, LIU Hong-xia, SUN Rui-yuan, ZHENG Qingshan. Study of mathematical models of scales for evaluating efficacy in symptomatology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(7): 808-813.
[6]	LV Ying-hua, ZHENG Qing-shan. Mathematical models and evaluations in study of medical measuring scale [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(6): 690-696.
[7]	HUANG Xiao-hui, SHI Jun, LI Jun, SONG Guo-qiang, XIE Hai-tang, ZHENG Qing-shan, SUN Ruiyuan. Pharmacokinetic-pharmacodynamic modeling and simulation:concepts and basic principles(2) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(3): 334-341.
[8]	HE Fu-yuan, ZHOU Hong-hao, LUO Jie-ying. Establishment of a network pharmacokinetic model for multiple component drugs and parameter analyses [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(12): 1321-1331.
[9]	HUANG Xiao-hui, SHI Jun, LI Jun, XIE Hai-tang, ZHENG Qing-shan, SUN Rui-yuan. Pharmacokinetic-pharmacodynamic modeling and simulation:concepts and basic principles(1) [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(1): 82-89.
[10]	LUAN Jia-jie, MA Zhang-qing, WANG Wu-san, GUI Chang-qing, SONG Jian-guo. Effects of co-administering probenecid orally on pharmacokinetics of cefaclor in rabbits [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2006, 11(2): 215-222.
[11]	ZHANG Xiu-Hong, MA Zhang-Qing, GUI Chang-Qing, SONG Jian-Guo. Effects of probenecid on pharmacokinetics of cefaclor in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(5): 523-526.
[12]	SHENG Yu-Cheng, ZHENG Qing-Shan. Population pharmacokinetics and its application in new drug development [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(12): 1333-1337.
[13]	WANG Chang-Sheng, LIU Xiao-Ping, MA Zhang-Qing, SONG Jian-Guo. Influence of probenecid on pharmacokinetics of cefaclor [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2002, 7(2): 130-133.
[14]	QIU Fu-Rong, JI Jin-Mei, CHENG Bo, ZENG Zhao-Hong, SUN Hua, MAO Guo-Guang. Relative bioavailablity of cefacloreffervescent tablets in human volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2000, 5(2): 142-144.
[15]	Yu Huixing, Cao Guoxian, Huang Xuquan. Establishment and application of imitative system adsorption chromatography [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 1997, 2(4): 264-266.